Streetbeat News

Price Targets

BIRK

Birkenstock Holding Plc (NYSE:BIRK) reported Q4 earnings with adjusted EPS of 14 cents, surpassing estimates by 75%, and sales of $407.67 million, exceeding estimates by 34.41%. The company provided FY 2024 guidance with expected revenue of $1.89 to $1.91 billion but anticipates adjusted EBITDA margin headwinds. Telsey Advisory Group maintained an Outperform rating and a $56 price target. Despite positive earnings, BIRK shares traded lower by 9.2% post-earnings.

Portfolio Pulse from Erica Kollmann

January 18, 2024 | 4:51 pm

BA

Susquehanna analyst Charles Minervino has maintained a Positive rating on Boeing (NYSE:BA) but has reduced the price target from $306 to $279.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 4:50 pm

ZG

JMP Securities analyst Nicholas Jones has reiterated a 'Market Outperform' rating on Zillow Group (NASDAQ:ZG) and maintained a price target of $60.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 4:43 pm

SCHW

JMP Securities analyst Devin Ryan has reiterated a 'Market Outperform' rating on Charles Schwab (NYSE:SCHW) and maintained a price target of $77.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 4:41 pm

HALO

JMP Securities analyst Jason Butler has reiterated a 'Market Outperform' rating on Halozyme Therapeutics (NASDAQ:HALO) and maintained a price target of $72.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 4:39 pm

CSGP

JMP Securities analyst Nicholas Jones has reiterated a 'Market Outperform' rating on CoStar Group (NASDAQ:CSGP) and maintained a price target of $90.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 4:37 pm

RRR

JMP Securities analyst Jordan Bender has reaffirmed a Market Outperform rating on Red Rock Resorts (NASDAQ:RRR) and increased the price target from $52 to $55.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 4:33 pm

HALO

Halozyme Therapeutics' stock price is trading lower following price target reductions by HC Wainwright and Goldman Sachs. Despite the news that argenx received approval in Japan for VYVDURA injection, which is co-formulated with Halozyme's ENHANZE technology, the lowered price targets have negatively impacted investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 4:28 pm

RITM

JMP Securities analyst Trevor Cranston has maintained a Market Outperform rating on Rithm Capital (NYSE:RITM) and increased the price target from $10.5 to $11.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 4:26 pm

PFLT

JMP Securities analyst Kevin Fitzsimmons has maintained a Market Outperform rating on PennantPark Floating Rate (NYSE:PFLT) and increased the price target from $12 to $12.5.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 4:24 pm